MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology
Diabetes & Endocrinology

Major Nature Study Redefines Obesity, Moving Beyond BMI to Transform Diagnosis and Treatment

MedXY Editorial TeamNov 15, 2026
obesity

Today, more than 1 billion people worldwide are affected by obesity. Despite its prevalence, the lack of a clear clinical definition of its disease state has hindered the recognition of obesity as a standalone disease—leading to gaps in diagnosis and treatment, inconsistent prevention efforts, misallocation of resources, and persistent stigma.

Traditionally, obesity has been assessed using Body Mass Index (BMI), calculated as , with the World Health Organization (WHO) defining a as overweight and as obese. However, as a surrogate measure of body size, BMI fails to account for differences in body composition or fat distribution, both of which directly influence health risks.

To address these limitations, the Lancet Diabetes & Endocrinology Commission proposed a new diagnostic framework for obesity in 2025, dividing the condition into two categories: clinical obesity (excess adiposity that has already impaired organ function or daily activities) and preclinical obesity (increased adiposity and elevated health risks, while organ and systemic functions remain intact). Where feasible, the framework also recommends supplementing BMI with additional anthropometric measures—such as waist circumference (WC), waist-to-height ratio (WHtR), or dual-energy X-ray absorptiometry (DEXA) fat quantification—to improve the detection of excess adiposity. Although conceptually aligned with medical diagnostic principles, the clinical utility of this new framework remained uncertain.

On November 11, 2026, an international team of researchers published a study in Nature titled: "Validation of clinical and preclinical obesity across global cohorts."

The study demonstrates that compared with traditional BMI-based definitions, the new framework proposed by the Lancet Commission identifies and defines obesity more accurately. It pinpoints high-risk clinical obesity with greater precision while reducing the overtreatment of low-risk preclinical obesity—thereby transforming clinical management and potentially improving patient outcomes.

Previously, it was unclear to what extent incorporating the additional anthropometric measurements recommended by the Lancet Commission would alter obesity classification compared with using BMI alone, or whether the distinction between clinical and preclinical obesity reflects meaningfully different health states. The natural progression of preclinical obesity—including how often it remains stable versus progressing to clinical obesity over time—was also unknown. More broadly, whether these classifications consistently correlate with clinical prognosis across diverse populations and healthcare settings remained to be validated.

In this latest study, the research team analyzed data from 844,108 adults across four major international cohorts (including the UK Biobank, All of Us, and SIDIAP). They evaluated the Lancet Commission’s diagnostic framework across several dimensions, including obesity classification, the distribution and longitudinal progression of clinical and preclinical obesity, and their associations with mortality.

The results revealed that the new framework classifies obesity far more effectively than traditional BMI-based definitions. Specifically, compared with the new framework—which combines waist circumference (WC) and waist-to-height ratio (WHtR) with BMI—relying on BMI alone overestimated obesity in 1.2%–3.1% of participants and underestimated it in 5.2%–8.6%. Overall, the new definition increased the total prevalence of obesity by 3.3%–7.4% compared with BMI alone.

Furthermore, under the new framework, clinical obesity accounted for 22.7%–31.3% of all obesity cases, representing a prevalence of 5.6%–10.9% in the general population. Among individuals with preclinical obesity at baseline, only 8.7%–22.6% progressed to clinical obesity within 10 years.

The study also highlighted the critical importance of distinguishing between clinical and preclinical obesity, as the two categories exhibit distinct health profiles and patient outcomes. Increased mortality risk was associated with obesity defined under the new framework, whereas no such association was observed when obesity was defined by BMI alone. Moreover, clinical obesity was linked to a significantly higher risk of all-cause mortality (), while preclinical obesity carried only a modest risk ().

Overall, the study shows that relying solely on BMI misclassifies obesity in a substantial portion of the population—both overestimating and underestimating the clinical significance of excess adiposity—and fails to effectively stratify higher mortality risks. Integrating additional anthropometric metrics (such as waist-to-height ratio and waist circumference) alongside clinical criteria reflecting organ function improves obesity detection and aligns diagnosis more closely with true disease status. Clinical and preclinical obesity represent distinct, common subgroups with markedly different mortality risks. These findings validate the clinical utility and prognostic value of differentiating between clinical and preclinical obesity, supporting the global adoption of the Lancet Commission’s new diagnostic framework to improve obesity care and public health policy.

Paper Link:

https://www.nature.com/articles/s41586-026-11237-5

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Retatrutide Once Weekly for Pain Management and Weight Loss in Adults with Knee Osteoarthritis and Obesity: A Clinical Review

Diabetes & EndocrinologyNov 19, 2026

Retatrutide: A Promising Triple Hormone Receptor Agonist for Obesity Management and Related Comorbidities

Diabetes & EndocrinologyNov 12, 2026

Enhancing Functional Capacity in Obesity: The Role of Functional Inspiratory Muscle Training

Diabetes & EndocrinologyNov 11, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story